Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

Mark J Sculpher; Greta Lozano-Ortega; Jennifer Sambrook; Stephen Palmer; Orges Ormanidhi; Ameet Bakhai; Marcus Flather; P Gabriel Steg; Shamir R Mehta; William Weintraub

doi:10.1016/j.ahj.2009.02.017

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

Mark J Sculpher, Greta Lozano-Ortega, Jennifer Sambrook, Stephen Palmer, Orges Ormanidhi, Ameet Bakhai, Marcus Flather, P Gabriel Steg, Shamir R Mehta, William Weintraub

Research output: Contribution to journal › Article › peer-review

49 Citations (Scopus)

Abstract

The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States.

Original language	English
Pages (from-to)	845-852
Number of pages	8
Journal	American Heart Journal
Volume	157
Issue number	5
DOIs	https://doi.org/10.1016/j.ahj.2009.02.017
Publication status	Published - May 2009

Keywords

Acute Coronary Syndrome
Anticoagulants
Cost-Benefit Analysis
Electrocardiography
Enoxaparin
Factor X
Follow-Up Studies
Guideline Adherence
Health Care Costs
Humans
Polysaccharides
Practice Guidelines as Topic
Time Factors
United States

Access to Document

10.1016/j.ahj.2009.02.017

Cite this

Sculpher, M. J., Lozano-Ortega, G., Sambrook, J., Palmer, S., Ormanidhi, O., Bakhai, A., Flather, M., Steg, P. G., Mehta, S. R., & Weintraub, W. (2009). Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. American Heart Journal, 157(5), 845-852. https://doi.org/10.1016/j.ahj.2009.02.017

Sculpher, Mark J ; Lozano-Ortega, Greta ; Sambrook, Jennifer et al. / Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes : short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. In: American Heart Journal. 2009 ; Vol. 157, No. 5. pp. 845-852.

@article{c98bfcf693f04acf84cabab25ddcfb06,

title = "Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial",

abstract = "The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States.",

keywords = "Acute Coronary Syndrome, Anticoagulants, Cost-Benefit Analysis, Electrocardiography, Enoxaparin, Factor X, Follow-Up Studies, Guideline Adherence, Health Care Costs, Humans, Polysaccharides, Practice Guidelines as Topic, Time Factors, United States",

author = "Sculpher, {Mark J} and Greta Lozano-Ortega and Jennifer Sambrook and Stephen Palmer and Orges Ormanidhi and Ameet Bakhai and Marcus Flather and Steg, {P Gabriel} and Mehta, {Shamir R} and William Weintraub",

year = "2009",

month = may,

doi = "10.1016/j.ahj.2009.02.017",

language = "English",

volume = "157",

pages = "845--852",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

number = "5",

}

Sculpher, MJ, Lozano-Ortega, G, Sambrook, J, Palmer, S, Ormanidhi, O, Bakhai, A, Flather, M, Steg, PG, Mehta, SR & Weintraub, W 2009, 'Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial', American Heart Journal, vol. 157, no. 5, pp. 845-852. https://doi.org/10.1016/j.ahj.2009.02.017

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes : short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. / Sculpher, Mark J; Lozano-Ortega, Greta; Sambrook, Jennifer et al.

In: American Heart Journal, Vol. 157, No. 5, 05.2009, p. 845-852.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes

T2 - short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

AU - Sculpher, Mark J

AU - Lozano-Ortega, Greta

AU - Sambrook, Jennifer

AU - Palmer, Stephen

AU - Ormanidhi, Orges

AU - Bakhai, Ameet

AU - Flather, Marcus

AU - Steg, P Gabriel

AU - Mehta, Shamir R

AU - Weintraub, William

PY - 2009/5

Y1 - 2009/5

N2 - The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States.

AB - The study aimed to compare the short-term costs and long-term cost-effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non-ST-elevation acute coronary syndrome in the United States.

KW - Acute Coronary Syndrome

KW - Anticoagulants

KW - Cost-Benefit Analysis

KW - Electrocardiography

KW - Enoxaparin

KW - Factor X

KW - Follow-Up Studies

KW - Guideline Adherence

KW - Health Care Costs

KW - Humans

KW - Polysaccharides

KW - Practice Guidelines as Topic

KW - Time Factors

KW - United States

U2 - 10.1016/j.ahj.2009.02.017

DO - 10.1016/j.ahj.2009.02.017

M3 - Article

C2 - 19376310

VL - 157

SP - 845

EP - 852

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -

Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. American Heart Journal. 2009 May;157(5):845-852. doi: 10.1016/j.ahj.2009.02.017